Medistim — Earnings Release 2021

Feb 25, 2022

4th quarter and preliminary year end results for 2021

4th quarter and preliminary year end results for 2021

All time high sales for a quarter, ending at MNOK 112.7 (MNOK 94.2), an increase of 19.7%. Full year 2021 sales ended at a record of MNOK 427.3 (MNOK 363.1). Currency neutral sales of own products increased by 38% for the quarter and 28% for the year.

Operating result (EBIT) for the quarter ended at MNOK 19.5 (MNOK 22.1). Operating result for 2021 ended at MNOK 116.3 MNOK 95.5), a 21.8% increase. This is the best operating result for a year ever. Cashflow from operations was a solid MNOK 127.5 for the year. Cash by the end of the year was MNOK 129.5.

Expert consensus paper published in the world-renowned journal Circulation with strong advocacy for the routine use of flow measurement technology.

The Board will suggest to the General Meeting a dividend of NOK 3.75 per share.